每經AI快訊(xun)，5月8日(ri)，康泰醫學(300869.SZ)公(gong)(gong)(gong)告(gao)(gao)稱，公(gong)(gong)(gong)司控(kong)股(gu)(gu)(gu)(gu)股(gu)(gu)(gu)(gu)東、實(shi)際(ji)控(kong)制人胡坤計劃在本公(gong)(gong)(gong)告(gao)(gao)披露之日(ri)起十五個交易(yi)日(ri)后的(de)(de)三個月內，以集中競價和大宗交易(yi)方式(shi)合(he)計減(jian)持公(gong)(gong)(gong)司股(gu)(gu)(gu)(gu)份(fen)不(bu)超(chao)過1200萬股(gu)(gu)(gu)(gu)，即不(bu)超(chao)過公(gong)(gong)(gong)司總股(gu)(gu)(gu)(gu)本的(de)(de)2.9865%。減(jian)持原因是股(gu)(gu)(gu)(gu)東自(zi)身資金需求，減(jian)持股(gu)(gu)(gu)(gu)份(fen)來(lai)源為公(gong)(gong)(gong)司首(shou)次公(gong)(gong)(gong)開發行(xing)股(gu)(gu)(gu)(gu)票并上(shang)市前取(qu)得的(de)(de)股(gu)(gu)(gu)(gu)份(fen)。